The Experts below are selected from a list of 33567 Experts worldwide ranked by ideXlab platform
Joseph Caprioli - One of the best experts on this subject based on the ideXlab platform.
-
feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid health maintenance organization
Ophthalmology, 2005Co-Authors: Brian J Song, Ervin N Fang, Joseph CaprioliAbstract:OBJECTIVE: To assess the feasibility of an automatic switch of a large number of patients with glaucoma or suspicion of glaucoma from latanoprost to bimatoprost, and to compare the efficacy of the 2 prostaglandin analogs before and after the switch. DESIGN: Retrospective nonrandomized comparison. PARTICIPANTS: Forty-three thousand four hundred forty-one California patients and 538 patients at one Southern California Clinical Facility of a nationwide prepaid health maintenance organization (HMO) who were on either prostaglandin between March 2002 and December 2003 (21 months). METHODS: Beginning in April 2002, patients on latanoprost were systemically switched to bimatoprost by the HMO pharmacy service after obtaining approval from the entire ophthalmology staff. PART 1: computerized dispensing records of California patients were retrieved. PART 2: medical records of patients at one Clinical Facility were reviewed. MAIN OUTCOME MEASURES: Rates of switching or switching back from one prostaglandin to another, intraocular pressure (IOP) control, and intolerability. RESULTS: PART 1: 17847 patients initially received latanoprost. Of them, 84.8% were switched from latanoprost to bimatoprost, and 13.0% were switched back to latanoprost. Twenty-five thousand five hundred ninety-four patients were started on bimatoprost without previous experience with latanoprost. Of them, 8.6% were later switched to latanoprost use instead. Patients who had previous experience with latanoprost had a statistically significantly higher rate of switching back to latanoprost after a period of bimatoprost use when compared with those who had no prior experience with latanoprost (13.0% vs. 8.6%, respectively; P 3 mmHg of IOP. The statistical significance of the IOP reduction after the switch remains in the monotherapy group (P = 0.005) but not in the multitherapy group (P = 0.058). Thirty-three patients (10.7%) who were switched from latanoprost to bimatoprost discontinued bimatoprost and resumed latanoprost. CONCLUSION: A systematic pharmacy-level switch from latanoprost to bimatoprost in a nationwide HMO achieved a high switch rate, with little switching back. There was a small but statistically significant reduction in mean IOP after the switch. An appreciable proportion of patients switched had a Clinically significant reduction of IOP.
-
feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid health maintenance organization
Ophthalmology, 2005Co-Authors: Simon Law, Brian J Song, Ervin N Fang, Joseph CaprioliAbstract:Objective To assess the feasibility of an automatic switch of a large number of patients with glaucoma or suspicion of glaucoma from latanoprost to bimatoprost, and to compare the efficacy of the 2 prostaglandin analogs before and after the switch. Design Retrospective nonrandomized comparison. Participants Forty-three thousand four hundred forty-one California patients and 538 patients at one Southern California Clinical Facility of a nationwide prepaid health maintenance organization (HMO) who were on either prostaglandin between March 2002 and December 2003 (21 months). Methods Beginning in April 2002, patients on latanoprost were systemically switched to bimatoprost by the HMO pharmacy service after obtaining approval from the entire ophthalmology staff. Part 1: computerized dispensing records of California patients were retrieved. Part 2: medical records of patients at one Clinical Facility were reviewed. Main Outcome Measures Rates of switching or switching back from one prostaglandin to another, intraocular pressure (IOP) control, and intolerability. Results Part 1: 17847 patients initially received latanoprost. Of them, 84.8% were switched from latanoprost to bimatoprost, and 13.0% were switched back to latanoprost. Twenty-five thousand five hundred ninety-four patients were started on bimatoprost without previous experience with latanoprost. Of them, 8.6% were later switched to latanoprost use instead. Patients who had previous experience with latanoprost had a statistically significantly higher rate of switching back to latanoprost after a period of bimatoprost use when compared with those who had no prior experience with latanoprost (13.0% vs. 8.6%, respectively; P P = 0.001). Forty-one patients (13.3%) had a decrease of >3 mmHg of IOP. The statistical significance of the IOP reduction after the switch remains in the monotherapy group ( P = 0.005) but not in the multitherapy group ( P = 0.058). Thirty-three patients (10.7%) who were switched from latanoprost to bimatoprost discontinued bimatoprost and resumed latanoprost. Conclusion A systematic pharmacy-level switch from latanoprost to bimatoprost in a nationwide HMO achieved a high switch rate, with little switching back. There was a small but statistically significant reduction in mean IOP after the switch. An appreciable proportion of patients switched had a Clinically significant reduction of IOP.
Brian J Song - One of the best experts on this subject based on the ideXlab platform.
-
feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid health maintenance organization
Ophthalmology, 2005Co-Authors: Brian J Song, Ervin N Fang, Joseph CaprioliAbstract:OBJECTIVE: To assess the feasibility of an automatic switch of a large number of patients with glaucoma or suspicion of glaucoma from latanoprost to bimatoprost, and to compare the efficacy of the 2 prostaglandin analogs before and after the switch. DESIGN: Retrospective nonrandomized comparison. PARTICIPANTS: Forty-three thousand four hundred forty-one California patients and 538 patients at one Southern California Clinical Facility of a nationwide prepaid health maintenance organization (HMO) who were on either prostaglandin between March 2002 and December 2003 (21 months). METHODS: Beginning in April 2002, patients on latanoprost were systemically switched to bimatoprost by the HMO pharmacy service after obtaining approval from the entire ophthalmology staff. PART 1: computerized dispensing records of California patients were retrieved. PART 2: medical records of patients at one Clinical Facility were reviewed. MAIN OUTCOME MEASURES: Rates of switching or switching back from one prostaglandin to another, intraocular pressure (IOP) control, and intolerability. RESULTS: PART 1: 17847 patients initially received latanoprost. Of them, 84.8% were switched from latanoprost to bimatoprost, and 13.0% were switched back to latanoprost. Twenty-five thousand five hundred ninety-four patients were started on bimatoprost without previous experience with latanoprost. Of them, 8.6% were later switched to latanoprost use instead. Patients who had previous experience with latanoprost had a statistically significantly higher rate of switching back to latanoprost after a period of bimatoprost use when compared with those who had no prior experience with latanoprost (13.0% vs. 8.6%, respectively; P 3 mmHg of IOP. The statistical significance of the IOP reduction after the switch remains in the monotherapy group (P = 0.005) but not in the multitherapy group (P = 0.058). Thirty-three patients (10.7%) who were switched from latanoprost to bimatoprost discontinued bimatoprost and resumed latanoprost. CONCLUSION: A systematic pharmacy-level switch from latanoprost to bimatoprost in a nationwide HMO achieved a high switch rate, with little switching back. There was a small but statistically significant reduction in mean IOP after the switch. An appreciable proportion of patients switched had a Clinically significant reduction of IOP.
-
feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid health maintenance organization
Ophthalmology, 2005Co-Authors: Simon Law, Brian J Song, Ervin N Fang, Joseph CaprioliAbstract:Objective To assess the feasibility of an automatic switch of a large number of patients with glaucoma or suspicion of glaucoma from latanoprost to bimatoprost, and to compare the efficacy of the 2 prostaglandin analogs before and after the switch. Design Retrospective nonrandomized comparison. Participants Forty-three thousand four hundred forty-one California patients and 538 patients at one Southern California Clinical Facility of a nationwide prepaid health maintenance organization (HMO) who were on either prostaglandin between March 2002 and December 2003 (21 months). Methods Beginning in April 2002, patients on latanoprost were systemically switched to bimatoprost by the HMO pharmacy service after obtaining approval from the entire ophthalmology staff. Part 1: computerized dispensing records of California patients were retrieved. Part 2: medical records of patients at one Clinical Facility were reviewed. Main Outcome Measures Rates of switching or switching back from one prostaglandin to another, intraocular pressure (IOP) control, and intolerability. Results Part 1: 17847 patients initially received latanoprost. Of them, 84.8% were switched from latanoprost to bimatoprost, and 13.0% were switched back to latanoprost. Twenty-five thousand five hundred ninety-four patients were started on bimatoprost without previous experience with latanoprost. Of them, 8.6% were later switched to latanoprost use instead. Patients who had previous experience with latanoprost had a statistically significantly higher rate of switching back to latanoprost after a period of bimatoprost use when compared with those who had no prior experience with latanoprost (13.0% vs. 8.6%, respectively; P P = 0.001). Forty-one patients (13.3%) had a decrease of >3 mmHg of IOP. The statistical significance of the IOP reduction after the switch remains in the monotherapy group ( P = 0.005) but not in the multitherapy group ( P = 0.058). Thirty-three patients (10.7%) who were switched from latanoprost to bimatoprost discontinued bimatoprost and resumed latanoprost. Conclusion A systematic pharmacy-level switch from latanoprost to bimatoprost in a nationwide HMO achieved a high switch rate, with little switching back. There was a small but statistically significant reduction in mean IOP after the switch. An appreciable proportion of patients switched had a Clinically significant reduction of IOP.
Ervin N Fang - One of the best experts on this subject based on the ideXlab platform.
-
feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid health maintenance organization
Ophthalmology, 2005Co-Authors: Brian J Song, Ervin N Fang, Joseph CaprioliAbstract:OBJECTIVE: To assess the feasibility of an automatic switch of a large number of patients with glaucoma or suspicion of glaucoma from latanoprost to bimatoprost, and to compare the efficacy of the 2 prostaglandin analogs before and after the switch. DESIGN: Retrospective nonrandomized comparison. PARTICIPANTS: Forty-three thousand four hundred forty-one California patients and 538 patients at one Southern California Clinical Facility of a nationwide prepaid health maintenance organization (HMO) who were on either prostaglandin between March 2002 and December 2003 (21 months). METHODS: Beginning in April 2002, patients on latanoprost were systemically switched to bimatoprost by the HMO pharmacy service after obtaining approval from the entire ophthalmology staff. PART 1: computerized dispensing records of California patients were retrieved. PART 2: medical records of patients at one Clinical Facility were reviewed. MAIN OUTCOME MEASURES: Rates of switching or switching back from one prostaglandin to another, intraocular pressure (IOP) control, and intolerability. RESULTS: PART 1: 17847 patients initially received latanoprost. Of them, 84.8% were switched from latanoprost to bimatoprost, and 13.0% were switched back to latanoprost. Twenty-five thousand five hundred ninety-four patients were started on bimatoprost without previous experience with latanoprost. Of them, 8.6% were later switched to latanoprost use instead. Patients who had previous experience with latanoprost had a statistically significantly higher rate of switching back to latanoprost after a period of bimatoprost use when compared with those who had no prior experience with latanoprost (13.0% vs. 8.6%, respectively; P 3 mmHg of IOP. The statistical significance of the IOP reduction after the switch remains in the monotherapy group (P = 0.005) but not in the multitherapy group (P = 0.058). Thirty-three patients (10.7%) who were switched from latanoprost to bimatoprost discontinued bimatoprost and resumed latanoprost. CONCLUSION: A systematic pharmacy-level switch from latanoprost to bimatoprost in a nationwide HMO achieved a high switch rate, with little switching back. There was a small but statistically significant reduction in mean IOP after the switch. An appreciable proportion of patients switched had a Clinically significant reduction of IOP.
-
feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid health maintenance organization
Ophthalmology, 2005Co-Authors: Simon Law, Brian J Song, Ervin N Fang, Joseph CaprioliAbstract:Objective To assess the feasibility of an automatic switch of a large number of patients with glaucoma or suspicion of glaucoma from latanoprost to bimatoprost, and to compare the efficacy of the 2 prostaglandin analogs before and after the switch. Design Retrospective nonrandomized comparison. Participants Forty-three thousand four hundred forty-one California patients and 538 patients at one Southern California Clinical Facility of a nationwide prepaid health maintenance organization (HMO) who were on either prostaglandin between March 2002 and December 2003 (21 months). Methods Beginning in April 2002, patients on latanoprost were systemically switched to bimatoprost by the HMO pharmacy service after obtaining approval from the entire ophthalmology staff. Part 1: computerized dispensing records of California patients were retrieved. Part 2: medical records of patients at one Clinical Facility were reviewed. Main Outcome Measures Rates of switching or switching back from one prostaglandin to another, intraocular pressure (IOP) control, and intolerability. Results Part 1: 17847 patients initially received latanoprost. Of them, 84.8% were switched from latanoprost to bimatoprost, and 13.0% were switched back to latanoprost. Twenty-five thousand five hundred ninety-four patients were started on bimatoprost without previous experience with latanoprost. Of them, 8.6% were later switched to latanoprost use instead. Patients who had previous experience with latanoprost had a statistically significantly higher rate of switching back to latanoprost after a period of bimatoprost use when compared with those who had no prior experience with latanoprost (13.0% vs. 8.6%, respectively; P P = 0.001). Forty-one patients (13.3%) had a decrease of >3 mmHg of IOP. The statistical significance of the IOP reduction after the switch remains in the monotherapy group ( P = 0.005) but not in the multitherapy group ( P = 0.058). Thirty-three patients (10.7%) who were switched from latanoprost to bimatoprost discontinued bimatoprost and resumed latanoprost. Conclusion A systematic pharmacy-level switch from latanoprost to bimatoprost in a nationwide HMO achieved a high switch rate, with little switching back. There was a small but statistically significant reduction in mean IOP after the switch. An appreciable proportion of patients switched had a Clinically significant reduction of IOP.
Simon Law - One of the best experts on this subject based on the ideXlab platform.
-
feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid health maintenance organization
Ophthalmology, 2005Co-Authors: Simon Law, Brian J Song, Ervin N Fang, Joseph CaprioliAbstract:Objective To assess the feasibility of an automatic switch of a large number of patients with glaucoma or suspicion of glaucoma from latanoprost to bimatoprost, and to compare the efficacy of the 2 prostaglandin analogs before and after the switch. Design Retrospective nonrandomized comparison. Participants Forty-three thousand four hundred forty-one California patients and 538 patients at one Southern California Clinical Facility of a nationwide prepaid health maintenance organization (HMO) who were on either prostaglandin between March 2002 and December 2003 (21 months). Methods Beginning in April 2002, patients on latanoprost were systemically switched to bimatoprost by the HMO pharmacy service after obtaining approval from the entire ophthalmology staff. Part 1: computerized dispensing records of California patients were retrieved. Part 2: medical records of patients at one Clinical Facility were reviewed. Main Outcome Measures Rates of switching or switching back from one prostaglandin to another, intraocular pressure (IOP) control, and intolerability. Results Part 1: 17847 patients initially received latanoprost. Of them, 84.8% were switched from latanoprost to bimatoprost, and 13.0% were switched back to latanoprost. Twenty-five thousand five hundred ninety-four patients were started on bimatoprost without previous experience with latanoprost. Of them, 8.6% were later switched to latanoprost use instead. Patients who had previous experience with latanoprost had a statistically significantly higher rate of switching back to latanoprost after a period of bimatoprost use when compared with those who had no prior experience with latanoprost (13.0% vs. 8.6%, respectively; P P = 0.001). Forty-one patients (13.3%) had a decrease of >3 mmHg of IOP. The statistical significance of the IOP reduction after the switch remains in the monotherapy group ( P = 0.005) but not in the multitherapy group ( P = 0.058). Thirty-three patients (10.7%) who were switched from latanoprost to bimatoprost discontinued bimatoprost and resumed latanoprost. Conclusion A systematic pharmacy-level switch from latanoprost to bimatoprost in a nationwide HMO achieved a high switch rate, with little switching back. There was a small but statistically significant reduction in mean IOP after the switch. An appreciable proportion of patients switched had a Clinically significant reduction of IOP.
H M Proskin - One of the best experts on this subject based on the ideXlab platform.
-
a Clinical investigation of the efficacy of a commercial mouthrinse containing 0 05 cetylpyridinium chloride to control established dental plaque and gingivitis
The Journal of clinical dentistry, 2009Co-Authors: M F Silva, William Devizio, B Stewart, H M ProskinAbstract:Objective The objective of this independent, double-blind, parallel, six-week Clinical study was to assess the efficacy of a commercially available mouthrinse containing 0.05% cetylpyridinium chloride (CPC) for controlling established dental plaque and gingivitis relative to that of a control mouthrinse without CPC. Methods Adult male and female subjects from the Maceio, Brazil area reported to the Clinical Facility, after having refrained from any oral hygiene procedures for 12 hours, and from eating, drinking, and smoking for four hours, for an assessment of the oral soft and hard tissues, and for a baseline gingivitis and dental plaque evaluation. Qualifying subjects were randomly assigned to one of the two treatment groups, and were provided with their assigned mouthrinse, and an adult soft-bristled toothbrush and toothpaste for home use. Over the six-week period of home use, during which there were no restrictions regarding diet or smoking habits, subjects were instructed to brush their teeth for one minute twice daily with the supplied toothbrush and a commercially available fluoride toothpaste, to rinse their mouths with water after brushing, and then to rinse with their assigned mouthrinse for one minute before expectorating. The use of any other oral hygiene products or procedures, such as floss or interdental stimulators, was not permitted during the study. After six weeks of product use, subjects returned to the Clinical Facility, having followed the same restrictions with respect to oral-hygiene procedures, eating and drinking, as with the baseline visit, and the oral soft and hard tissue assessments and gingivitis and dental plaque evaluations were repeated. Results One-hundred and ten subjects complied with the protocol and completed the study. With regard to supragingival plaque, after six weeks of product use, the subjects using the 0.05% CPC mouthrinse exhibited statistically significant reductions from baseline in whole-mouth Plaque Index scores (32.1%), in Plaque Index scores measured at interproximal sites (31.3%), and in Plaque Severity Index scores (84.8%). Subjects using the control mouthrinse exhibited statistically significant reductions from baseline in whole-mouth Plaque Index scores (7.0%), in Plaque Index scores measured at interproximal sites (6.4%), and in Plaque Severity Index scores (24.5%). When compared to the control mouthrinse group, the 0.05% CPC mouthrinse group presented statistically significant greater reductions in whole-mouth Plaque Index scores (27.9%), in Plaque Index scores measured at interproximal sites (27.9%), and in Plaque Severity Index scores (81.1%) after six weeks of product use. With regard to gingivitis, after six weeks of product use, subjects using the 0.05% CPC mouthrinse exhibited statistically significant reductions from baseline in whole-mouth Gingival Index scores (25.0%), in Gingival Index scores measured at interproximal sites (25.3%), and in Gingivitis Severity Index scores (42.4%). Subjects using the control mouthrinse exhibited statistically significant reductions from baseline in whole-mouth Gingival Index scores (6.5%), in Gingival Index scores measured at interproximal sites (5.5%), and in Gingivitis Severity Index scores (11.6%). When compared to the control mouthrinse group, the 0.05% CPC mouthrinse group presented statistically significant greater reductions in whole-mouth Gingival Index scores (19.8%), in Gingival Index scores measured at interproximal sites (20.7%), and in Gingivitis Severity Index scores (35.5%) after six weeks of product use. Conclusion The results of this double-blind, parallel, six-week Clinical study support the conclusion that a mouthrinse containing 0.05% CPC is efficacious for controlling established dental plaque and gingivitis. As measurements were conducted 12 hours after product use, the results also demonstrate that the 0.5% CPC mouthrinse provides 12-hour protection against plaque and gingivitis.
-
Clinical investigation of the efficacy of a commercial mouthrinse containing 0 05 cetylpyridinium chloride in preventing dental plaque
The Journal of clinical dentistry, 2009Co-Authors: Roberto Fraga Moreira Lotufo, William Devizio, B Stewart, Caroline Morini Calil, Hsu Shao Feng, Ricardo Takiy Sekiguchi, H M ProskinAbstract:OBJECTIVE The objective of this independent, double-blind, seven-day Clinical study was to assess the efficacy of a commercially available mouthrinse containing 0.05% CPC for controlling dental plaque relative to that of a control mouthrinse without 0.05% CPC. METHODS Adult male and female subjects from the San Juan, Puerto Rico area reported to the Clinical Facility, having refrained from any oral hygiene procedures for 12 hours, and from eating, drinking, and smoking for four hours, for an assessment of the oral soft and hard tissues and a baseline dental plaque evaluation. Qualifying subjects were randomly assigned into one of the two treatment groups, and were provided with their assigned mouthrinse, an adult soft-bristled toothbrush, and a commercially available fluoride toothpaste for home use. Over the seven-day period of home use, during which there were no restrictions regarding diet or smoking habits, subjects were instructed to brush their teeth for one minute twice daily (morning and evening) with the toothbrush and toothpaste supplied, to rinse their mouths with water after brushing, and then to rinse with 15 ml of their assigned mouthrinse for one minute before expectorating. The use of other oral hygiene products or procedures, such as floss or interdental stimulators, was not permitted during the study. After seven days of product use, subjects returned to the Clinical Facility having followed the same restrictions with respect to oral hygiene procedures, eating, and drinking as prior to the baseline examination, and the oral soft and hard tissue assessments and dental plaque evaluations were repeated. Comparisons between treatment groups with respect to baseline-adjusted Plaque Index scores at the seven-day examination were performed using Analyses of Covariance, p < or = 0.05. RESULTS Forty-eight subjects complied with the protocol and completed the study. Results demonstrated that, after seven days of product use and 12 hours after rinsing, both the CPC mouthrinse group and the control mouthrinse group exhibited statistically significant reductions in whole-mouth Plaque Index scores (25.3% and 6.6%, respectively), in Plaque Index scores measured at interproximal sites (51.3% and 32.9%, respectively), and in Plaque Severity Index scores (43.5% and 25.4%, respectively). Relative to the control mouthrinse, the 0.05% CPC mouthrinse group exhibited statistically significant greater reductions in whole-mouth plaque scores (15.9%), in Plaque Index scores measured at interproximal sites (23%), and in Plaque Severity Index scores (17%). As the measurements were made 12 hours after final product use, the results also demonstrate that the CPC mouthrinse provides 12-hour protection against plaque accumulation in individuals with existing plaque. CONCLUSION The overall results of this double-blind Clinical study support the conclusion that after seven days of product use, a mouthrinse containing 0.05% CPC provides significantly greater efficacy for reducing dental plaque 12 hours after use, than does a control mouthrinse without 0.05% CPC.
-
a Clinical investigation of the efficacy of two dentifrices for controlling oral malodor and plaque microflora overnight
The Journal of clinical dentistry, 2008Co-Authors: Yun Po Zhang, William Devizio, H M ProskinAbstract:OBJECTIVE The objective of this independent, double-blind, overnight Clinical study was to assess the efficacy of a dentifrice containing 0.3% triclosan/2.0% polyvinylmethyl ether/maleic acid (PVM/MA) copolymer/0.243% sodium fluoride in a 17% dual silica base (Colgate Total Advanced Toothpaste) for the overnight control of oral malodor and plaque microflora, relative to that of a commercially available dentifrice containing 0.243% sodium fluoride in a silica base (Crest Cavity Protection Toothpaste). METHODS After a five-day period using a supplied commercially available fluoride toothpaste, adult male and female subjects from the Chengdu, China area reported to the Clinical Facility in the evening, after having refrained from the use of all oral hygiene procedures, as well as eating and drinking, for at least six hours. Following an assessment of the oral soft and hard tissues, subjects were evaluated for baseline oral malodor by a panel of four trained judges using a nine-point hedonic scale. Plaque samples (baseline) from the teeth on the left side of subjects' mouths were also collected. Subjects who presented a mean baseline oral malodor score between 6.0 and 8.4 were stratified according to their oral malodor score and randomly assigned within strata to one of the two treatment groups. Subjects were provided with their assigned dentifrice and instructed to brush their teeth on the left side of their mouth only, for one minute under supervision. Subjects returned to the testing Facility the following morning for an overnight evaluation, having refrained from the use of all oral hygiene procedures, and from eating and drinking. An oral malodor assessment was performed, plaque samples were collected from the teeth on the right side of the mouth, and a final oral soft and hard tissue evaluation was performed. RESULTS Eighty-one (81) subjects completed the study. At the overnight evaluation, subjects in the triclosan/copolymer/fluoride dentifrice group and the fluoride dentifrice group presented mean oral malodor scores of 4.91 and 6.86, respectively. Relative to the fluoride dentifrice group, at the overnight evaluation the triclosan/copolymer/fluoride dentifrice group presented a statistically significant 28.4% reduction in oral malodor scores. Additionally, at the overnight evaluation, subjects in the triclosan/ copolymer/fluoride dentifrice group and the fluoride dentifrice group presented geometric mean microbial colony forming unit (CFU) scores of 3.15 and 6.07, respectively. Relative to the fluoride dentifrice group, at the overnight evaluation the triclosan/copolymer/ fluoride dentifrice group presented a statistically significant 49.5% reduction in microbial CFU scores. CONCLUSION The overall results of this double-blind Clinical study support the conclusion that a single evening's use of a dentifrice containing 0.3% triclosan/2.0% PVM/MA copolymer/0.243% sodium fluoride in a 17% dual silica base provides statistically significantly lower levels of overnight (12-hour) oral malodor and plaque microflora when compared to a commercially available dentifrice containing 0.243% sodium fluoride in a silica base.